- Home
- IGC vs MDAI Comparison
IGC vs MDAI Comparison
Compare IGC & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGC
- MDAI
- Stock Information
- Founded
- IGC 2005
- MDAI 2013
- Country
- IGC United States
- MDAI United States
- Employees
- IGC N/A
- MDAI N/A
- Industry
- IGC Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- IGC Health Care
- MDAI Health Care
- Exchange
- IGC Nasdaq
- MDAI Nasdaq
- Market Cap
- IGC 29.4M
- MDAI 27.8M
- IPO Year
- IGC N/A
- MDAI N/A
- Fundamental
- Price
- IGC $0.31
- MDAI $1.37
- Analyst Decision
- IGC Strong Buy
- MDAI Strong Buy
- Analyst Count
- IGC 2
- MDAI 2
- Target Price
- IGC $3.88
- MDAI $4.75
- AVG Volume (30 Days)
- IGC 392.1K
- MDAI 443.4K
- Earning Date
- IGC 02-18-2025
- MDAI 05-06-2025
- Dividend Yield
- IGC N/A
- MDAI N/A
- EPS Growth
- IGC N/A
- MDAI N/A
- EPS
- IGC N/A
- MDAI N/A
- Revenue
- IGC $1,236,000.00
- MDAI $27,264,000.00
- Revenue This Year
- IGC N/A
- MDAI $61.78
- Revenue Next Year
- IGC $18.34
- MDAI N/A
- P/E Ratio
- IGC N/A
- MDAI N/A
- Revenue Growth
- IGC 1.64
- MDAI 44.52
- 52 Week Low
- IGC $0.26
- MDAI $0.82
- 52 Week High
- IGC $0.91
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- IGC 52.84
- MDAI 27.17
- Support Level
- IGC $0.26
- MDAI $1.44
- Resistance Level
- IGC $0.34
- MDAI $1.78
- Average True Range (ATR)
- IGC 0.02
- MDAI 0.12
- MACD
- IGC 0.01
- MDAI -0.05
- Stochastic Oscillator
- IGC 65.88
- MDAI 7.04
About IGC IGC Pharma Inc.
IGC Pharma Inc develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol-based formulation that is in a 146-person Phase 2 clinical trial for agitation in dementia due to Alzheimer's. IGC also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.